The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2021 | CITE-seq analysis predicts response to CAR-T therapy and bispecifics in myeloma
Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) is a single cell sequencing method that enables detailed immunophenotypic profiling and transcriptomic analysis of cells on a single cell level. Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, talks on the use of CITE-seq in multiple myeloma patients undergoing CAR-T or bispecific antibody therapy. Analyzing the immunophenotypic profile of a patient’s T-cells prior to treatment can predict if they are likely to respond to the therapy. T-cells in the bone marrow and peripheral blood of sensitive patients are more central memory-like, whereas an exhausted T-cell phenotype if often seen in those resistant to CAR-T therapy and bispecifics. Transcriptomic data analysis is also beneficial to improve our understanding of the drivers of T-cell phenotypes. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Speaker bureau/honoraria: BMS, Janssen
Consulting fees: BMS, Janssen
